China Pharma Holdings, Inc.

AI-generated fair value estimate for this company.

Method: Net asset value approach: total assets of $44.71M less total liabilities of $8.53M ($36.18M book equity) per the June 30, 2026 10-Q, plus an estimated $4.43M net proceeds from a subsequent equity offering, divided by an estimated post-offering diluted share count of about 50.6M shares (43.02M existing plus roughly 7.6M newly issued).

Reasoning: China Pharma Holdings has thin and declining revenue ($3.91M TTM) with a net loss and negative working capital, making a forward FCF DCF unreliable, so book net asset value is a more defensible floor-value method given the company's worth rests mainly in its existing manufacturing assets and working capital rather than projected cash generation.